论文部分内容阅读
【目的】探讨曲妥珠单抗联合不同化疗药物治疗乳腺癌的临床疗效。【方法】收集整理2007年1月至2010年1月期间在本院接受曲妥珠单抗治疗的97例乳腺癌患者的临床资料，其中单用曲妥珠单抗(A组)治疗的30例，曲妥珠单抗联合长春瑞滨方案(B 组)治疗者33例，曲妥珠单抗联合紫杉醇方案(C)治疗者34例。比较分析不同方案的治疗效果、治疗期间的毒副反应及患者生存情况。【结果】B 组治疗乳腺癌患者的总有效为36.36%，疾病控制率为78.78%；C组治疗乳腺癌患者的总有效率为32.35%，疾病控制率为67.65%；两组临床总有效率及疾病控制率均显著高于 A 组，且差异有显著性(P <0.05)；治疗期间曲妥珠单抗联合不同化疗方案治疗乳腺癌患者的耐受性良好，未出现治疗相关性死亡；曲妥珠单抗联合化疗药物治疗后1、2、5年生存率均均显著高于单用曲妥珠单抗(P 0.05)。【结论】曲妥珠单抗联合不同化疗药物治疗乳腺癌的临床疗效优于单用曲妥珠单抗，且患者毒副作用均可耐受，值得临床推广应用。“,”[Objective]To study the clinical effect of trastuzumab therapy with the combination of chemo-therapy drugs for treatment of breast cancer.[Methods]97 cases of patients with breast cancer undergoing trastuzumab combined with different chemotherapy drugs in our hospital were collected from January 2007 to January 2010,among which 30 cases (Group A)were treated with trastuzumab only,33 cases(Group B)with trastuzumab plus vinorelbine ,and 34 cases (Group C)with trastuzumab combined with paclitaxel .A retro-spective analysis of the effects of different treatment programs was undertaken on therapeutic efficacy,toxic and adverse effects and patient survival situation.[Results]Total effective of Group B for the treatment of pa-tients with breast cancer is 36.36% with its disease control rate 78.78%;Total effective of Group C was 32.35% ,and its disease control rate 67.65%;The total clinical effectives and disease control rates of the two groups were significantly higher than those of Group A,with obvious difference there exits (P 0.05 )[Conclusion]Combination therapy of trastuzumab with different chemotherapy drugs for treatment of breast cancer is clinically superior to that of trastuzumab alone.The toxic and adverse effects herewith are well tolerated.Thus ,it is worth of clinical application.